Amgen rises as 3rd-qtr financials come in ahead of forecasts

29 October 2020
amgen_large

US biotech giant Amgen (Nasdaq: AMGN) announced financial results for the third quarter of 2020 at close of market on Wednesday, showing that total revenues increased 12% to $6.42 billion, just ahead of analyst estimates of $6.38 billion, driven by higher volume growth, partially offset by lower net selling prices and the effects of the COVID-19 pandemic.

Amgen shares advanced 1.2% in after-hours trading, following a 3.2% decline in the regular session to close at $216.38.

Product sales increased 12% globally, driven by 18% volume growth across a number of Amgen’s newer products, including Otezla (apremilast), Mvasi (bevacizumab-awwb), Kanjinti (trastuzumab-anns), and Repatha (evolocumab), partially offset by declines in select products from the impact of COVID-19, and biosimilar and generic competition.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology